Neumora Therapeutics Inc
NMRA2.560USD
-0.020-0.78%
收盘 11/07, 16:00（美东）报价延迟15分钟
414.07M总市值
亏损市盈率 TTM
关于 Neumora Therapeutics Inc 公司
Neumora Therapeutics Inc. 是一家临床阶段的生物制药公司。该公司的治疗产品线包括七个临床和临床前神经科学项目，旨在为广泛的未得到充分治疗的神经精神疾病和神经退行性疾病提供新的治疗机制。其先进的候选产品 navacaprant (NMRA-140) 是一种新型的每日一次口服 kappa 阿片受体 (KOR) 拮抗剂，正在开发用于治疗抑郁症 (MDD)。其其他候选药物包括 NMRA-266、NMRA-511 和 NMRA-NMDA。NMRA-266 是 M4 毒蕈碱受体 (M4R) 的正变构调节剂程序，用于治疗精神分裂症。NMRA-266 旨在选择性地针对毒蕈碱受体家族的 M4 受体亚型。 NMRA-511 是一种在研的加压素 1a 受体 (V1aR) 拮抗剂。NMRA-NMDA 是一种 NMDA 正向变构调节剂方案，该公司正在开发该方案用于治疗精神分裂症。
Neumora Therapeutics Inc简介
公司代码NMRA
公司名称Neumora Therapeutics Inc
上市日期Sep 15, 2023
CEOMr. Paul L. Berns
员工数量110
证券类型Ordinary Share
年结日Sep 15
公司地址490 Arsenal Way
城市WATERTOWN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02472
电话18577600900
网址https://neumoratx.com/
公司代码NMRA
上市日期Sep 15, 2023
CEOMr. Paul L. Berns
Neumora Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.68M
+3.27%
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
130.51K
+46.75%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
+72.78%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
22.47K
-8.09%
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Jason G. Duncan
Mr. Jason G. Duncan
Chief Legal and Administrative Officer
Chief Legal and Administrative Officer
--
--
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. David Piacquad
Mr. David Piacquad
Independent Director
Independent Director
--
--
Mr. Alaa A. Halawa
Mr. Alaa A. Halawa
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.68M
+3.27%
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
130.51K
+46.75%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
+72.78%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
22.47K
-8.09%
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 10月2日 周四
更新时间: 10月2日 周四
持股股东
股东类型
持股股东
持股股东
占比
Amgen Inc
21.84%
ARCH Venture Partners
20.90%
Berns (Paul L)
4.74%
SB Global Advisers Ltd
4.04%
Invus Public Equities Advisors, LLC
2.69%
其他
45.79%
持股股东
持股股东
占比
Amgen Inc
21.84%
ARCH Venture Partners
20.90%
Berns (Paul L)
4.74%
SB Global Advisers Ltd
4.04%
Invus Public Equities Advisors, LLC
2.69%
其他
45.79%
股东类型
持股股东
占比
Venture Capital
22.04%
Corporation
21.84%
Investment Advisor
21.62%
Individual Investor
5.65%
Hedge Fund
5.33%
Investment Advisor/Hedge Fund
3.10%
Endowment Fund
2.04%
Research Firm
0.70%
Family Office
0.05%
其他
17.61%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
293
86.79M
53.64%
-40.47M
2025Q2
288
142.02M
87.70%
-25.57M
2025Q1
283
144.00M
90.43%
+12.16M
2024Q4
249
161.18M
99.54%
+45.20M
2024Q3
201
148.65M
93.66%
+40.67M
2024Q2
179
142.61M
90.03%
+47.65M
2024Q1
154
133.89M
85.01%
+50.39M
2023Q4
108
122.49M
78.90%
+50.97M
2023Q3
54
110.63M
71.42%
+110.63M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Amgen Inc
35.37M
21.84%
--
--
Apr 10, 2025
ARCH Venture Partners
31.93M
19.72%
--
--
Nov 12, 2024
Berns (Paul L)
7.68M
4.74%
+242.77K
+3.27%
Apr 10, 2025
SB Global Advisers Ltd
6.54M
4.04%
--
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
4.36M
2.69%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
4.76M
2.94%
-562.13K
-10.56%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.50M
2.16%
+6.35K
+0.18%
Jun 30, 2025
Wellcome Trust
3.31M
2.04%
--
--
Jun 30, 2025
ICONIQ Capital, LLC
2.56M
1.58%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.55M
1.58%
-3.09M
-54.78%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Biotechnology ETF
0.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares US Small-Cap Equity Factor ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Schwab U.S. Broad Market ETF
0%
查看更多
ProShares Ultra Nasdaq Biotechnology
占比0.03%
Invesco Nasdaq Biotechnology ETF
占比0.03%
Invesco RAFI US 1500 Small-Mid ETF
占比0.01%
iShares Biotechnology ETF
占比0.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比0%
Schwab U.S. Small-Cap ETF
占比0%
iShares US Small-Cap Equity Factor ETF
占比0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0%
Fidelity MSCI Health Care Index ETF
占比0%
Schwab U.S. Broad Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
